Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo

Virology

Volumn 389, Issue 1-2, 2009, Pages 108-121

  Banerjee, Kaustuv ^a   Andjelic, Sofija ^b   Klasse, Per Johan ^a   Kang, Yun ^b   Sanders, Rogier W ^a   Michael, Elizabeth ^a   Durso, Robert J ^b   Ketas, Thomas J ^a   Olson, William C ^b   Moore, John P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b A Subsidiary of Lantheus Holdings   (United States)

Author keywords

AIDS; Antibodies; Glycoproteins; gp120; HIV 1; IL 10 receptor blockade; Immune suppression; Mannose; T cells; Vaccine

Indexed keywords

GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR ANTIBODY; MANNOSE; MONOCLONAL ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME MECHANISM; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; IMMUNOGLOBULIN G; INTERLEUKIN-10; MANNOSE; MANNOSIDASES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEUTRALIZATION TESTS; RECEPTORS, INTERLEUKIN-10; T-LYMPHOCYTES, HELPER-INDUCER;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 67349176314     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.04.001     Document Type: Article

References (77)

1. Aguilar J.C., and Rodriguez E.G. Vaccine adjuvants revisited. Vaccine 25 19 (2007) 3752-3762
2. Allaway G.P., Ryder A.M., Beaudry G.A., and Maddon P.J. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. AIDS Res. Hum. Retroviruses 9 7 (1993) 581-587
3. Barcova M., Kacani L., Speth C., and Dierich M.P. gp41 envelope protein of human immunodeficiency virus induces interleukin (IL)-10 in monocytes, but not in B, T, or NK cells, leading to reduced IL-2 and interferon-gamma production. J. Infect. Dis. 177 4 (1998) 905-913
4. Beddows S., Schulke N., Kirschner M., Barnes K., Franti M., Michael E., Ketas T., Sanders R.W., Maddon P.J., Olson W.C., and Moore J.P. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 79 14 (2005) 8812-8827
5. Bergman M.P., Engering A., Smits H.H., van Vliet S.J., van Bodegraven A.A., Wirth H.P., Kapsenberg M.L., Vandenbroucke-Grauls C.M., van Kooyk Y., and Appelmelk B.J. Helicobacter pylori modulates the T helper cell 1/T helper cell 2 balance through phase-variable interaction between lipopolysaccharide and DC-SIGN. J. Exp. Med. 200 8 (2004) 979-990
6. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., and Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 23 (2004) 13232-13252
7. Biswas P.S., Pedicord V., Ploss A., Menet E., Leiner I., and Pamer E.G. Pathogen-specific CD8 T cell responses are directly inhibited by IL-10. J. Immunol. 179 7 (2007) 4520-4528
8. Brady M.T., MacDonald A.J., Rowan A.G., and Mills K.H. Hepatitis C virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes. Eur. J. Immunol. 33 12 (2003) 3448-3457
9. Brooks D.G., Trifilo M.J., Edelmann K.H., Teyton L., McGavern D.B., and Oldstone M.B. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 12 11 (2006) 1301-1309
10. Brooks D.G., Lee A.M., Elsaesser H., McGavern D.B., and Oldstone M.B. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J. Exp. Med. 205 3 (2008) 533-541
11. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., Gruber G., Tauer C., Steindl F., Jungbauer A., et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 10 4 (1994) 359-369
12. Bungener L., Geeraedts F., Ter Veer W., Medema J., Wilschut J., and Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26 19 (2008) 2350-2359
13. Burton D.R., Barbas III C.F., Persson M.A., Koenig S., Chanock R.M., and Lerner R.A. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. U. S. A. 88 22 (1991) 10134-10137
14. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., and Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5 3 (2004) 233-236
15. Cavacini L., Duval M., Song L., Sangster R., Xiang S.H., Sodroski J., and Posner M. Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base. Aids 17 5 (2003) 685-689
16. Clapham P.R., and McKnight A. Cell surface receptors, virus entry and tropism of primate lentiviruses. J. Gen. Virol. 83 Pt 8 (2002) 1809-1829
17. Clerici M., Wynn T.A., Berzofsky J.A., Blatt S.P., Hendrix C.W., Sher A., Coffman R.L., and Shearer G.M. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J. Clin. Invest. 93 2 (1994) 768-775
18. Connor R.I., Korber B.T., Graham B.S., Hahn B.H., Ho D.D., Walker B.D., Neumann A.U., Vermund S.H., Mestecky J., Jackson S., Fenamore E., Cao Y., Gao F., Kalams S., Kunstman K.J., McDonald D., McWilliams N., Trkola A., Moore J.P., and Wolinsky S.M. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72 2 (1998) 1552-1576
19. Couper K.N., Blount D.G., and Riley E.M. IL-10: the master regulator of immunity to infection. J. Immunol. 180 9 (2008) 5771-5777
20. Daly L.M., Johnson P.A., Donnelly G., Nicolson C., Robertson J., and Mills K.H. Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HIV gp120. Vaccine 23 7 (2005) 963-974
21. Ding Y., Chen D., Tarcsafalvi A., Su R., Qin L., and Bromberg J.S. Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses. J. Immunol. 170 3 (2003) 1383-1391
22. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., and Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453 7198 (2008) 1122-1126
23. Evel-Kabler K., Song X.T., Aldrich M., Huang X.F., and Chen S.Y. SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J. Clin. Invest. 116 1 (2006) 90-100
24. Fernando G.J., Stewart T.J., Tindle R.W., and Frazer I.H. Vaccine-induced Th1-type responses are dominant over Th2-type responses in the short term whereas pre-existing Th2 responses are dominant in the longer term. Scand. J. Immunol. 47 5 (1998) 459-465
25. Foulds K.E., Rotte M.J., and Seder R.A. IL-10 is required for optimal CD8 T cell memory following Listeria monocytogenes infection. J. Immunol. 177 4 (2006) 2565-2574
26. Geijtenbeek T.B., Van Vliet S.J., Koppel E.A., Sanchez-Hernandez M., Vandenbroucke-Grauls C.M., Appelmelk B., and Van Kooyk Y. Mycobacteria target DC-SIGN to suppress dendritic cell function. J. Exp. Med. 197 1 (2003) 7-17
27. Ghosh M., and Bandyopadhyay S. Interaction of Leishmania parasites with dendritic cells and its functional consequences. Immunobiology 209 1-2 (2004) 173-177
28. Gilbert P.B., Peterson M.L., Follmann D., Hudgens M.G., Francis D.P., Gurwith M., Heyward W.L., Jobes D.V., Popovic V., Self S.G., Sinangil F., Burke D., and Berman P.W. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191 5 (2005) 666-677
29. Gorny M.K., Conley A.J., Karwowska S., Buchbinder A., Xu J.Y., Emini E.A., Koenig S., and Zolla-Pazner S. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66 12 (1992) 7538-7542
30. Gorse G.J., Corey L., Patel G.B., Mandava M., Hsieh R.H., Matthews T.J., Walker M.C., McElrath M.J., Berman P.W., Eibl M.M., and Belshe R.B. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses 15 2 (1999) 115-132
31. Graham B.S., McElrath M.J., Connor R.I., Schwartz D.H., Gorse G.J., Keefer M.C., Mulligan M.J., Matthews T.J., Wolinsky S.M., Montefiori D.C., Vermund S.H., Lambert J.S., Corey L., Belshe R.B., Dolin R., Wright P.F., Korber B.T., Wolff M.C., and Fast P.E. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J. Infect. Dis. 177 2 (1998) 310-319
32. Grundner C., Pancera M., Kang J.M., Koch M., Sodroski J., and Wyatt R. Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. Virology 330 1 (2004) 233-248
33. Grundner C., Li Y., Louder M., Mascola J., Yang X., Sodroski J., and Wyatt R. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology 331 1 (2005) 33-46
34. Gupta S., and Mitra D. Human immunodeficiency virus-1 Tat protein: immunological facets of a transcriptional activator. Indian J. Biochem. Biophys. 44 5 (2007) 269-275
35. Gurney K.B., Elliott J., Nassanian H., Song C., Soilleux E., McGowan I., Anton P.A., and Lee B. Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa. J. Virol. 79 9 (2005) 5762-5773
36. Humphreys I.R., de Trez C., Kinkade A., Benedict C.A., Croft M., and Ware C.F. Cytomegalovirus exploits IL-10-mediated immune regulation in the salivary glands. J. Exp. Med. 204 5 (2007) 1217-1225
37. Jankovic D., Caspar P., Zweig M., Garcia-Moll M., Showalter S.D., Vogel F.R., and Sher A. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J. Immunol. 159 5 (1997) 2409-2417
38. Karlsson Hedestam G.B., Fouchier R.A., Phogat S., Burton D.R., Sodroski J., and Wyatt R.T. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 6 2 (2008) 143-155
39. Klasse P.J., and Moore J.P. Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects?. Virology 323 1 (2004) 1-8
40. Kool M., Soullie T., van Nimwegen M., Willart M.A., Muskens F., Jung S., Hoogsteden H.C., Hammad H., and Lambrecht B.N. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205 4 (2008) 869-882
41. Koppel E.A., Ludwig I.S., Appelmelk B.J., van Kooyk Y., and Geijtenbeek T.B. Carbohydrate specificities of the murine DC-SIGN homologue mSIGNR1. Immunobiology 210 2-4 (2005) 195-201
42. Leonard C.K., Spellman M.W., Riddle L., Harris R.J., Thomas J.N., and Gregory T.J. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265 18 (1990) 10373-10382
43. Li Y., Chu N., Rostami A., and Zhang G.X. Dendritic cells transduced with SOCS-3 exhibit a tolerogenic/DC2 phenotype that directs type 2 Th cell differentiation in vitro and in vivo. J. Immunol. 177 3 (2006) 1679-1688
44. McIntyre T.M., Klinman D.R., Rothman P., Lugo M., Dasch J.R., Mond J.J., and Snapper C.M. Transforming growth factor beta 1 selectivity stimulates immunoglobulin G2b secretion by lipopolysaccharide-activated murine B cells. J. Exp. Med. 177 4 (1993) 1031-1037
45. Montefiori D., Sattentau Q., Flores J., Esparza J., and Mascola J. Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med. 4 12 (2007) e348
46. Moore J.P., and Jarrett R.F. Sensitive ELISA for the gp120 and gp160 surface glycoproteins of HIV-1. AIDS Res. Hum. Retroviruses 4 5 (1988) 369-379
47. Moore J.P., and Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70 3 (1996) 1863-1872
48. Moore J.P., McCutchan F.E., Poon S.W., Mascola J., Liu J., Cao Y., and Ho D.D. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J. Virol. 68 12 (1994) 8350-8364
49. Moore A., McCarthy L., and Mills K.H. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 17 20-21 (1999) 2517-2527
50. Moore K.W., de Waal Malefyt R., Coffman R.L., and O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19 (2001) 683-765
51. Moore J.P., Kitchen S.G., Pugach P., and Zack J.A. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 20 1 (2004) 111-126
52. Orsilles M.A., Pieri E., Cooke P., and Caula C. IL-2 and IL-10 serum levels in HIV-1-infected patients with or without active antiretroviral therapy. Apmis 114 1 (2006) 55-60
53. Pantophlet R., and Burton D.R. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24 (2006) 739-769
54. Parren P.W., Gauduin M.C., Koup R.A., Poignard P., Fisicaro P., Burton D.R., and Sattentau Q.J. Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunol. Lett. 57 1-3 (1997) 105-112
55. Pollock K.G., Conacher M., Wei X.Q., Alexander J., and Brewer J.M. Interleukin-18 plays a role in both the alum-induced T helper 2 response and the T helper 1 response induced by alum-adsorbed interleukin-12. Immunology 108 2 (2003) 137-143
56. Quaranta M.G., Napolitano A., Sanchez M., Giordani L., Mattioli B., and Viora M. HIV-1 Nef impairs the dynamic of DC/NK crosstalk: different outcome of CD56(dim) and CD56(bright) NK cell subsets. FASEB J. 21 10 (2007) 2323-2334
57. Redpath S., Angulo A., Gascoigne N.R., and Ghazal P. Murine cytomegalovirus infection down-regulates MHC class II expression on macrophages by induction of IL-10. J. Immunol. 162 11 (1999) 6701-6707
58. Robinson J.E., Holton D., Pacheco-Morell S., Liu J., and McMurdo H. Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines. AIDS Res. Hum. Retroviruses 6 5 (1990) 567-579
59. Roque S., Nobrega C., Appelberg R., and Correia-Neves M. IL-10 underlies distinct susceptibility of BALB/c and C57BL/6 mice to Mycobacterium avium infection and influences efficacy of antibiotic therapy. J. Immunol. 178 12 (2007) 8028-8035
60. Sanders R.W., Venturi M., Schiffner L., Kalyanaraman R., Katinger H., Lloyd K.O., Kwong P.D., and Moore J.P. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76 14 (2002) 7293-7305
61. Scanlan C.N., Pantophlet R., Wormald M.R., Ollmann Saphire E., Stanfield R., Wilson A., Katinger H., Dwek R.A., Rudd P.M., and Burton D.R. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1→2 mannose residues on the outer face of gp120. J. Virol. 76 14 (2002) 7306-7321
62. Seubert A., Monaci E., Pizza M., O'Hagan D.T., and Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 180 8 (2008) 5402-5412
63. Shan M., Klasse P.J., Banerjee K., Dey A.K., Iyer S.P., Dionisio R., Charles D., Campbell-Gardener L., Olson W.C., Sanders R.W., and Moore J.P. HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog. 3 11 (2007) e169
64. Snapper C.M., McIntyre T.M., Mandler R., Pecanha L.M., Finkelman F.D., Lees A., and Mond J.J. Induction of IgG3 secretion by interferon gamma: a model for T cell-independent class switching in response to T cell-independent type 2 antigens. J. Exp. Med. 175 5 (1992) 1367-1371
65. Song X.T., Aldrich M., and Chen S.Y. Suppressor of cytokine signaling 1 inhibition strategy to enhance anti-HIV vaccination. Expert Rev. Vaccines 5 4 (2006) 495-503
66. Srikanth P., Castillo R.C., Sridharan G., John T.J., Zachariah A., Mathai D., and Schwartz D.H. Increase in plasma IL-10 levels and rapid loss of CD4+ T cells among HIV-infected individuals in south India. Int. J. STD. AIDS 11 1 (2000) 49-51
67. Stevens T.L., Bossie A., Sanders V.M., Fernandez-Botran R., Coffman R.L., Mosmann T.R., and Vitetta E.S. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334 6179 (1988) 255-258
68. Sun H.X., Xie Y., and Ye Y.P. Advances in saponin-based adjuvants. Vaccine 27 12 (2009) 1787-1796
69. Takahashi H., Takeshita T., Morein B., Putney S., Germain R.N., and Berzofsky J.A. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 344 6269 (1990) 873-875
70. Tangsinmankong N., Day N.K., Good R.A., and Haraguchi S. Different mechanisms are utilized by HIV-1 Nef and staphylococcal enterotoxin A to control and regulate interleukin-10 production. Immunol. Lett. 84 2 (2002) 97-101
71. Thali M., Moore J.P., Furman C., Charles M., Ho D.D., Robinson J., and Sodroski J. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67 7 (1993) 3978-3988
72. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., and Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70 2 (1996) 1100-1108
73. Trujillo J.R., Rogers R., Molina R.M., Dangond F., McLane M.F., Essex M., and Brain J.D. Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor. Proc. Natl. Acad. Sci. U. S. A. 104 12 (2007) 5097-5102
74. van Liempt E., van Vliet S.J., Engering A., Garcia Vallejo J.J., Bank C.M., Sanchez-Hernandez M., van Kooyk Y., and van Die I. Schistosoma mansoni soluble egg antigens are internalized by human dendritic cells through multiple C-type lectins and suppress TLR-induced dendritic cell activation. Mol. Immunol. 44 10 (2007) 2605-2615
75. Walker B.D., and Burton D.R. Toward an AIDS vaccine. Science 320 5877 (2008) 760-764
76. Weiner H.L. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect. 3 11 (2001) 947-954
77. Wyatt R., Moore J., Accola M., Desjardin E., Robinson J., and Sodroski J. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69 9 (1995) 5723-5733